Cover Image
市場調查報告書

視神經病變:全球臨床實驗趨勢

Optic Neuropathy Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 324942
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
視神經病變:全球臨床實驗趨勢 Optic Neuropathy Global Clinical Trials Review, H2, 2016
出版日期: 2016年10月31日 內容資訊: 英文 55 Pages
簡介

視神經病變是一般性非發炎性眼科疾病,是視神經組織的功能障礙或破壞所引起。這個疾病的原因為血液供給中斷、腫瘤及動脈瘤的壓迫、營養不良、化學藥品造成的毒性效果等。

本報告提供視神經病變相關之臨床研究最新趨勢分析,提供您疾病·治療方法概要,及主要國家的臨床實驗狀況,地區·Phase·階段別進展,並彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

簡介

  • 視神經病變
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要國家的臨床實驗數量
    • 歐洲主要5個國家的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量

G7各國臨床實驗數量:眼科治療藥臨床實驗中視神經病變的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:眼科治療藥臨床實驗中視神經病變的比例

E7各國的各階段臨床實驗數量

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

視神經病變治療藥臨床實驗的主要參與企業

有潛力的藥劑

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Sigma-Tau S.p.A.
    • SBI Biotech Co., Ltd.
    • Regenera Pharma Ltd.
    • Highmark Inc.
    • Eli Lilly and Company
    • Bayer AG
    • Allergan, Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • Tehran University of Medical Sciences
    • Shahid Beheshti University of Medical Sciences
    • Hong Kong Eye Hospital
    • Second Military Medical University
    • Jikei University School of Medicine
    • Isfahan University of Medical Sciences
    • Mount Sinai Hospital
    • University of Colorado
    • University Hospital Tubingen
    • National Eye Institute

5個有代表性的臨床實驗簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3833CTIDB

GlobalData's clinical trial report, "Optic Neuropathy Global Clinical Trials Review, H2, 2016" provides an overview of Optic Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Optic Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Clinical Trials by G7 Countries: Proportion of Optic Neuropathy to Ophthalmology Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials in G7 Countries by Trial Status 15
  • Clinical Trials by E7 Countries: Proportion of Optic Neuropathy to Ophthalmology Clinical Trials 16
  • Clinical Trials by Phase in E7 Countries 17
  • Clinical Trials in E7 Countries by Trial Status 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Optic Neuropathy Therapeutics Clinical Trials 26
  • Prominent Drugs 28
  • Clinical Trial Profile Snapshots 29

Appendix 52

  • Abbreviations 52
  • Definitions 52
  • Research Methodology 53
  • Secondary Research 53
  • About GlobalData 54
  • Contact Us 54
  • Disclaimer 54
  • Source 55

List of Tables

  • Optic Neuropathy Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Optic Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Optic Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Optic Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Optic Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Optic Neuropathy Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Optic Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
  • Proportion of Optic Neuropathy to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 13
  • Optic Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
  • Optic Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
  • Proportion of Optic Neuropathy to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 16
  • Optic Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
  • Optic Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
  • Optic Neuropathy Therapeutics, Global, Clinical Trials by Phase, 2016* 19
  • Optic Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 20
  • Optic Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
  • Optic Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
  • Optic Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures

  • Optic Neuropathy Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Optic Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Optic Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Optic Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Optic Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Optic Neuropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Optic Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
  • Proportion of Optic Neuropathy to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 13
  • Optic Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
  • Optic Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
  • Proportion of Optic Neuropathy to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 16
  • Optic Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
  • Optic Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 18
  • Optic Neuropathy Therapeutics, Global, Clinical Trials by Phase (%), 2016* 19
  • Optic Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 20
  • Optic Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
  • Optic Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
  • Optic Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
  • Optic Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
  • GlobalData Methodology 53
Back to Top